The Effects of Different Doses and Patterns of Docetaxel Chemotherapy in Japanese Patients with Castration-Resistant Prostate Cancer

摘要

Based on the results of large docetaxel phase 3 studies of the TAX327 and SWOG9916 studies, tri-weekly docetaxel is currently the standard therapeutic course for castration-resistant prostate cancer (CRPC) [1]. However, because Japanese patients have tended to show a higher rate of adverse effects, including febrile-neutro-penia, various doses and patterns of docetaxel have been administered in Japan [2]. This study retrospectively assessed the effectiveness of 3 patterns of docetaxel chemotherapy, including tri-weekly, bi-weekly, and weekly therapy, in Yokohama City University Medical Center and 13 affiliated hospitals.